Universal (UVV) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Fiscal year 2025 saw a 7% increase in revenue and a 5% rise in operating income over FY24, driven by strong tobacco demand and growth in the Universal Ingredients business.
The company declared its 55th consecutive annual dividend increase, with a quarterly dividend of $0.82 per share, reflecting a commitment to shareholder value.
Strategic priorities include maximizing the tobacco business, expanding Universal Ingredients, and strengthening organizational efficiency and human capital management.
Sustainability remains a core focus, with the release of the 2024 Sustainability Report highlighting progress in supply chain resiliency, labor standards, and energy efficiency.
Voting matters and shareholder proposals
Shareholders are to vote on: (1) election of three directors for three-year terms, (2) a non-binding advisory resolution on executive compensation, and (3) ratification of Ernst & Young LLP as independent auditor for FY26.
The Board recommends voting FOR all director nominees, FOR the executive compensation resolution, and FOR auditor ratification.
Board of directors and corporate governance
The Board is divided into three classes, with three nominees up for election: Lennart R. Freeman, Fotini E. Manolios, and Preston D. Wigner.
Board members bring diverse skills in audit, sustainability, executive leadership, finance, and risk oversight.
The Board includes a Lead Independent Director and five standing committees, all with independent directors.
Corporate governance guidelines, a code of conduct, and prohibitions on hedging and pledging company securities are in place.
Latest events from Universal
- Revenue and profit fell, but tobacco stayed strong and liquidity improved with new credit facility.UVV
Q3 20269 Feb 2026 - Q1 FY2025 revenue up 15% and operating income up 56%, with strong demand across segments.UVV
Q1 20252 Feb 2026 - Strategy centers on tobacco leadership, scaling ingredients, and sustainable, profitable growth.UVV
28th Annual ICR Conference 202613 Jan 2026 - Proxy covers director elections, say-on-pay, auditor ratification, and strong ESG focus.UVV
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, approve pay, and ratify auditor, with updated proxy card.UVV
Proxy Filing1 Dec 2025 - Revenue up 7% to $2.95B, operating income up 5%, with strong segment growth and improved liquidity.UVV
Q4 202526 Nov 2025 - Operating income nearly doubled on strong tobacco margins, despite higher costs and tariff risks.UVV
Q1 202623 Nov 2025 - Revenue and net income increased, offsetting margin pressures and supporting growth initiatives.UVV
Q2 202613 Nov 2025 - Digital-first growth, strong Asia expansion, and premium wellness products drive performance.UVV
Investor Presentation27 Jun 2025